Hikma expands in the Tunisian market
30th Mar 2010 09:38
Pharmaceutical firm Hikma has agreed to increase its interest in Industries Pharmaceutiques Ibn Al Baytar, a Tunisian pharmaceutical manufacturing and marketing company, to 66%. Hikma will pay a consideration of $5million for the additional interest which will be satisfied from existing cash resour
Read moreThursday tips round-up: Hikma, IG Group, Derwent
18th Mar 2010 06:12
Hikma's forecast of "low teens" growth in branded drugs in 2010 was lower than some stockbrokers ? such as Panmure Gordon ? had been expecting. The corollary is that Hikma expects US generic drugs and injectable medicines, its two other businesses, to grow more strongly than before. But at 580p, d
Read moreLondon close: Gains pared at the close
17th Mar 2010 16:48
London's gains were trimmed just before the close as traders took a few profits before heading off to celebrate St. Patrick's Day. Nevertheless, it was the highest close for the Footsie since the middle of 2008. Mining stocks led the advance, despite conflicting views in the broking community on th
Read moreLondon afternoon: Brokers in miners disagreement
17th Mar 2010 14:29
A firm opening by Wall Street gave UK shares an additional fillip over the lunchtime trading session. Miners are leading the advance, despite conflicting views in the broking community on their merits. Societe Generale is in the bearish camp, cutting sector giants BHP Billiton and Rio Tinto from 'b
Read moreBroker tips: Kingfisher, Man Group, Hikma
17th Mar 2010 12:49
Hedge fund manager Man Group is comfortably the highest yielding stock among FTSE 100 constituents, but a rebasing - a City euphemism for a cut - of the dividend could be on the way, according to Morgan Stanley. The shares are currently yielding 11.77% based on historical dividend payments and thou
Read moreLondon midday: Arriva bid lifts mood
17th Mar 2010 12:02
London is now handily higher, with the strength of transport groups and miners cancelling out the subdued performance of ex-dividend stocks such as HSBC, Standard Life and Thomas Cook. The main point of interest is confirmation from bus and rail group Arriva that it has had an unsolicited bid appr
Read moreBroker snap: Disappointing growth guidance at Hikma
17th Mar 2010 11:45
Broker Panmure Gordon was predicting yesterday that results from Hikma would be ahead of market expectations, so the in-line with consensus performance from the generic drugs producer came as a disappointment. The outlook statement also served to sap market enthusiasm for the stock in early trading
Read moreSector movers: Hikma weighs on pharma sector
17th Mar 2010 11:40
Hikma Pharmaceuticals is weighing on the pharmaceutical sector even after it reported a 33% increase in 2009 operating profit and said it was confident of continuing growth. Broker Panmure Gordon was predicting yesterday that results from Hikma would be ahead of market expectations, so the in-line
Read moreFTSE 250 movers: Arriva pulls away
17th Mar 2010 11:39
Arriva has raced into the lead to lead the FTSE 250 after the rail and bus group said it had received an approach about a possible offer. Shares in the company climbed yesterday amid rumours of a possible 700p-a-share bid from German transport operator Deutsche Bahn. Singaporean firm ComfortDelGr
Read moreHikma sees low teens sales growth in 2010
17th Mar 2010 07:30
Hikma Pharmaceuticals reported a 33% increase in 2009 operating profit and said it was confident of continuing growth. The Jordan based drug maker said it expects to increase sales in the "low-teens" in 2010. Operating profit rose 33% for the year ended 31 December 2009 to £107.3m. Revenue for the
Read moreWednesday preview: UK unemployment, MPC minutes, Hikma
16th Mar 2010 18:03
In the absence of any announcements expected from FTSE 100 companies attention may be focused on economic data on Wednesday. Claimant count unemployment for February is expected to show a small rise, following on from the 23,500 increase in January. Forecasting agency IHS Global Insight is tipping
Read moreHikma to market BioCryst drug in MENA region
11th Jan 2010 14:32
Hikma Pharmaceuticals has signed an exclusive agreement to market BioCryst's H1N1 treatment peramivir with governments in the Middle East and North Africa (MENA) region. 'This agreement reinforces our position as the partner of choice in the MENA region,' said chief executive Said Darwazah. 'BioC
Read morePetropavlovsk chief banks £24m
18th Dec 2009 16:17
Pavel Maslovskiy, chief executive of Petropavlovsk, is taking advantage of the near-record gold price to bank some cash with the sale of £24m worth of shares in the Russian gold miner. Companies associated with Dr Maslovskiy sold 2m shares at £11.93 per share. The off-market sale was to a non-relat
Read moreThursday preview: Diageo, Hikma, IMI
26th Aug 2009 14:48
Alcoholic drinks group Diageo's trading update is expected to report an improvement in full-year pre-tax profits on Thursday, with the market consensus hovering around £2.bn, compared to £2.09bn last year. This is despite an anticipated decline in revenue to around £9.25bn from £10.64bn in the year
Read moreLondon close: Footsie adds to week's gains
17th Jul 2009 16:28
Footsie rounded off its best week since March with more gains. Miners were prominent among the risers. Eurasian Natural Resources, Xstrata, Vedanta Resources and Rio Tinto are doing well. British Airways climbed after saying it is raising £600m, including a £300m convertible issue and another £30
Read more